Literature DB >> 24438371

Obestatin levels are associated with C-peptide and antiinsulin antibodies at the onset, whereas unacylated and acylated ghrelin levels are not predictive of long-term metabolic control in children with type 1 diabetes.

Flavia Prodam1, Francesco Cadario, Simonetta Bellone, Letizia Trovato, Stefania Moia, Erica Pozzi, Silvia Savastio, Gianni Bona.   

Abstract

CONTEXT AND
OBJECTIVE: Ghrelin secretion is altered at the onset and after the start of insulin therapy in children with type 1 diabetes. Contemporary regulation of acylated ghrelin (AG), unacylated ghrelin (UAG), and obestatin (OBST) remains undefined in this disease. It is unknown as to whether they could be good predictors of changes in glucose and metabolic control. DESIGN, SETTING, AND
SUBJECTS: This was a longitudinal study conducted in a tertiary care center. AG, UAG, and OBST were measured at baseline and after 2 years of follow-up in 51 children and adolescents with a history of type 1 diabetes extending beyond 1 year. A total of 33 healthy matched subjects were used as controls.
RESULTS: Age-, puberty-, and body mass index-adjusted UAG levels were lower (P < .005) and OBST levels were higher (P < .009) in children with type 1 diabetes, with respect to controls. AG levels were similar to controls, but all ratios of the three peptides are altered in diabetic patients. OBST (P < .05) was negatively correlated with C-peptide (P < .05) and insulin antibodies (P < .008) at the onset of diabetes. In diabetic patients, baseline AG and UAG levels were negatively correlated with insulin dosage in the short and long term (P < .001). AG, but not OBST, was positively correlated with C-peptide levels 2 years after diagnosis (P < .05). Overall, the peptides were not predictive of glucose and metabolic control.
CONCLUSIONS: UAG, AG, OBST, and their ratios are differently regulated in children with type 1 diabetes, suggesting a role in the metabolic balance of the disease, with insulin a likely regulator of AG and UAG. The peptides do not appear to be good long-term predictors of glucose control, with further investigations needed to explain whether OBST could be a precocious predictor of islet dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24438371     DOI: 10.1210/jc.2013-3294

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Behavioural implications of traditional treatment and closed-loop automated insulin delivery systems in Type 1 diabetes: applying a cognitive restraint theory framework.

Authors:  A R Kahkoska; E J Mayer-Davis; K K Hood; D M Maahs; K S Burger
Journal:  Diabet Med       Date:  2017-09-11       Impact factor: 4.359

Review 2.  Ghrelin's Relationship to Blood Glucose.

Authors:  Bharath K Mani; Kripa Shankar; Jeffrey M Zigman
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

Review 3.  Topical review: a comprehensive risk model for disordered eating in youth with type 1 diabetes.

Authors:  Claire M Peterson; Sarah Fischer; Deborah Young-Hyman
Journal:  J Pediatr Psychol       Date:  2014-12-10

4.  Unacylated ghrelin and obestatin: promising biomarkers of protein energy wasting in children with chronic kidney disease.

Authors:  Alice Monzani; Michela Perrone; Flavia Prodam; Stefania Moia; Giulia Genoni; Sara Testa; Fabio Paglialonga; Anna Rapa; Gianni Bona; Giovanni Montini; Alberto Edefonti
Journal:  Pediatr Nephrol       Date:  2017-11-18       Impact factor: 3.714

5.  Understanding antagonism and synergism: A qualitative assessment of weight management in youth with Type 1 diabetes mellitus.

Authors:  Anna R Kahkoska; Madison E Watts; Kimberly A Driscoll; Franziska K Bishop; Paul Mihas; Joan Thomas; Jennifer R Law; Nina Jain; Elizabeth J Mayer-Davis
Journal:  Obes Med       Date:  2018-02-22

6.  Ghrelin Protects Against Insulin-Induced Hypoglycemia in a Mouse Model of Type 1 Diabetes Mellitus.

Authors:  Kripa Shankar; Deepali Gupta; Bharath K Mani; Brianna G Findley; Sherri Osborne-Lawrence; Nathan P Metzger; Chen Liu; Eric D Berglund; Jeffrey M Zigman
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-11       Impact factor: 5.555

7.  Instrument Context Relevance Evaluation, Translation, and Psychometric Testing of the Diabetes Eating Problem Survey-Revised (DEPS-R) among People with Type 1 Diabetes in China.

Authors:  Wencong Lv; Qinyi Zhong; Jia Guo; Jiaxin Luo; Jane Dixon; Robin Whittemore
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

Review 8.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

9.  Overweight and obesity in type 1 diabetes is not associated with higher ghrelin concentrations.

Authors:  Behiye Özcan; Patric J D Delhanty; Martin Huisman; Jenny A Visser; Sebastian J Neggers; Aart Jan van der Lely
Journal:  Diabetol Metab Syndr       Date:  2021-07-22       Impact factor: 3.320

Review 10.  "A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes".

Authors:  Deepali Gupta; Sean B Ogden; Kripa Shankar; Salil Varshney; Jeffrey M Zigman
Journal:  Mol Metab       Date:  2020-11-25       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.